Impact of Novel MDR Modulators on Human Cancer Cells: Reversal Activities and Induction Studies
- 133 Downloads
Novel multidrug resistance (mdr) modulators have been proved as inhibitors of P-glycoprotein (P-gp). We first investigated the in vitro effects of selected compounds in human cancer cells on multidrug resistance reversal effects compared to drug standards and on P-gp induction to characterize the potential of the compounds as clinical candidates.
The uptake of daunorubicin into a parental cancer cell line and P-gp expressing subcell line in presence of the modulators was characterized by flow cytometry. Induction of P-gp was investigated in P-gp expressing and non-expressing cancer cell lines on the RNA level by real-time quantitative polymerase chain reaction (RTQ-PCR) and protein quantification. Results were additionally confirmed by northern blot techniques and functionality assays in selected cell lines.
The novel modulators showed activities as mdr reversers in a P-gp specific human cancer cell model with mainly increased uptake rates of daunorubicin into the drug-resistant cell line. H17 proved to be more active than cyclosporine A as a known strong mdr modulator. The induction studies revealed practically no induction potential of the compounds in usual short-time drug application regimes in all cell lines. Furthermore, the novel modulators did not increase the efflux of a P-gp model substrate in the functionality model assay. This confirmed the results of non-P-gp induction which was observed on both the RNA and the protein levels.
The novel mdr modulators proved as perspective candidates for further clinical studies because they turned out to be highly active in human cancer cell models. Furthermore, they showed no potential to induce the transmembrane efflux pump P-gp. This is a significant advantage compared to modulators which failed in clinical trials because of induction-effects that increase cellular resistances and, moreover, side effects in normal cells.
KEY WORDSflow cytometry induction studies mdr modulators P-glycoprotein reversal effects
The work was financially supported by the EU within the COSTB16 action, the BMBF within a bilateral DAAD exchange program and the DFG within the projects HI 687/5-1 and LA 1039/5-1.
- 6.H. Matsui, A. Takeshita, K. Naito, K. Shinjo, K. Shigeno, M. Maekawa, Y. Yamakawa, M. Tanimoto et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug-resistance modifiers. Leukemia. 16:813–819 (2002).PubMedCrossRefGoogle Scholar
- 7.H. Minderman, Y. Zhou, K. L. Ó Loughlin, and M. R. Baer. Bortezumib activity and in vitro interactions with anthracyclines and cytarabine in acute leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother. Pharmacol. 60:245–255 (2007) doi: 10.1007/s00280-006-0367-6.PubMedCrossRefGoogle Scholar
- 18.A. Hilgeroth, and A. Langner. First bioanalytical evaluation of nonpeptidic cage dimeric HIV-1 protease inhibitor N-benzyl 4-Aryl-1,4-dihydropyridine H17: biotransformation and toxicity on hep G2 cells. Arch. Pharm. Pharm. Med. Chem. 333:32–34 (2000) doi: 10.1002/(SICI)1521-4184(200001)333:1<32::AID-ARDP32>3.0.CO;2-Q.CrossRefGoogle Scholar
- 24.M. D. Perloff, L. L. Von Moltke, J. E. Marchand, and D. J. Greenblatt. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci. 90:1829–1837 (2001) doi: 10.1002/jps.1133.PubMedCrossRefGoogle Scholar
- 25.D. Sharples, G. Hajos, Z. Riedel, D. Csanyi, and J. Molnár. Ellipticine analogues and related compounds as inhibitors of reverse transcriptase and as inhibitors of the efflux pump. Arch. Pharm. Pharm. Med. Chem. 334:269–274 (2001) doi: 10.1002/1521-4184(200109)334:8/9<269::AID-ARDP269>3.0.CO;2-#.CrossRefGoogle Scholar
- 28.We decided to choose this colon carcinoma cell line COLO-320 for protein quantification using western blot and northern blot analyses because it is known from literature (29) that compared to the Caco-2 cell line which expresses several efflux pumps including P-gp at a lower protein level the P-gp levels in COLO-320 are sufficient enough for a comparison of the protein content before and after induction studies by western and northern blot analyses, respectively.Google Scholar